Products - Osteoporosis | Topic | NICE

Showing 15 products

Date | Title

Abaloparatide for treating osteoporosis after menopause (TA991)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 August 2024
Romosozumab for treating severe osteoporosis (TA791)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2022
Bisphosphonates for treating osteoporosis (TA464)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
8 July 2019
Published:
9 August 2017
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
7 February 2018
Published:
27 October 2008
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
7 February 2018
Published:
27 October 2008
Osteoporosis: assessing the risk of fragility fracture (CG146)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
7 February 2017
Published:
8 August 2012
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2013
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2010
Bindex for investigating suspected osteoporosis (MIB106)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
31 May 2017
Osteoporosis (QS149)
Product type:
Quality standard
Published:
28 April 2017
Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
20 August 2025
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 TS ID 11807
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osteoporosis
Status:
Awaiting development
Expected publication date:
TBC